Sodium Benzoate

DUBLIN, Aug. 23, 2023 /PRNewswire/ -- The "Global Urea Cycle Disorders Treatment Market 2017-2027" report has been added to ResearchAndMarkets.com's offering. The global urea cycle disorders treatment market is poised for impressive growth in the forecast period from 2023 to 2027. This upward trajectory is fueled by a combination of factors, including the increasing prevalence of urea cycle disorders and substantial research and development efforts. Various catalysts are propelling this market's expansion, including heightened investments in research and development, growing initiatives by key industry players, heightened awareness, improved healthcare services, and a surge in innovative diagnostic methods. Rising Prevalence of Urea Cycle Disorders A surge in the prevalence of urea cycle disorders is expected to drive global market growth. Reports from the Centers for Disease Control and Prevention (CDC) indicate a projected incidence of 1 in 8500 births for urea cycle disorders. However, the actual number may be higher due to undiagnosed cases. It is estimated that up to 20% of Sudden Infant Death Syndrome (SIDS) cases may be attributed to undiagnosed inborn metabolic errors such as urea cycle disorders. This underscores the urgency of addressing and treating these disorders, thus catalyzing growth in the urea cycle disorders treatment market. Initiatives and Awareness Fueling Growth Governments and private organizations worldwide have ramped up efforts to support market growth. These initiatives encompass substantial investments in research and development, increased awareness campaigns, extensive research endeavors, clinical trials, and streamlined regulatory approvals. For instance, the merger of Mead Johnson Nutrition Company (MJN) with Reckitt Benckiser Group plc (RB) in 2017 bolstered the dietary management of urea cycle disorders by integrating brands like Enfa and Nutramigen into RB's consumer health portfolio. Similarly, Horizon Pharma plc's UCD in Common initiative offers resources and support for individuals with urea cycle disorders and their families. Leading Players and Geographic Outlook Market players shaping the global urea cycle disorders treatment market landscape include: Bausch Health Companies Inc. Recordati Rare Diseases Eurocept Pharmaceuticals Holding (Lucane Pharma SA) Acer Therapeutics Ultragenyx Pharmaceutical Aeglea BioTherapeutics Arcturus Therapeutics, Inc. Orpharma Pty. Ltd. Selecta Biosciences, Inc Abbott Laboratories, Inc. In terms of geographic spread, the United States is anticipated to be a pivotal market due to its escalating cases of urea cycle disorders. Conclusion: Navigating the Path Forward As the global urea cycle disorders treatment market marches ahead, it is driven by an amalgamation of factors that recognize the critical importance of addressing these genetic disorders. The rising prevalence, backed by initiatives, investments, and awareness, underscores the market's growth potential. A meticulously segmented market landscape, comprising diverse enzyme deficiency types, treatment options, routes of administration, and distribution channels, reflects the multifaceted approach adopted to combat urea cycle disorders. Amid these dynamics, leading players are contributing their expertise, while geographic trends emphasize the significance of targeted interventions. As the market evolves, it holds the promise of transforming lives and healthcare outcomes on a global scale. Report Scope In this report, global urea cycle disorders treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below. Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type: Carbamyl Phosphate Synthetase (CPS1) N-Acetylglutamate Synthetase (NAGS) Ornithine Transcarbamylase (OTC Deficiency) Argininosuccinic Acid Synthetase (AS) Argininosuccinate Lyase (AL or ASA Lyase) Arginase (AG) Urea Cycle Disorders Treatment Market, By Treatment Type: Amino Acid Formulas Phenylbutyrate Sodium Benzoate Others Urea Cycle Disorders Treatment Market, By Route of Administration: Oral Intravenous Urea Cycle Disorders Treatment Market, By Distribution Channel: Hospital Pharmacies Retail Pharmacies Online Pharmacies Urea Cycle Disorders Treatment Market, By Region: North America Asia-Pacific Europe & CIS South America Middle East & Africa Key Topics Covered 1. Product Overview 2. Research Methodology 3. Impact of COVID-19 on Global Urea Cycle Disorders Treatment Market 4. Voice of Customer 5. Executive Summary 6. Global Urea Cycle Disorders Treatment Market Outlook 7. North America Urea Cycle Disorders Treatment Market Outlook 8. Europe Urea Cycle Disorders Treatment Market Outlook 9. Asia-Pacific Urea Cycle Disorders Treatment Market Outlook 10. South America Urea Cycle Disorders Treatment Market Outlook 11. Middle East and Africa Urea Cycle Disorders Treatment Market Outlook 12. Market Dynamics 13. Market Trends & Developments 14. Competitive Landscape 15. Strategic Recommendations For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

NEWTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for Q4 and full year ended December 31, 2022, and provided an update on the Company’s recent corporate developments. “2022 marked Acer’s first U.S. Food and Drug Administration (FDA) product approval, for OLPRUVA™ (sodium phenylbutyrate), an innovative and responsibly priced treatment option for certain people with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS),” commented Chris Schelling, CEO and Founder of Acer. “We remain committed to our mission to provide transformative treatments to underserved and overlooked patients with rare and life-threatening diseases and will continue to focus our resources on launch preparation for OLPRUVA™ as well as continued pivotal Phase 3 clinical trial evaluation of EDSIVO™ for vEDS, both of which are subject to additional capital.” Q4 2022 and Recent Highlights OLPRUVA™ (sodium phenylbutyrate) for oral suspension In October 2022, Acer was issued a Notice of Allowance from the US Patent and Trademark Office (USPTO) for US patent application No. 16/624,834 (now issued as US Patent No. 11,517,547) for claims related to a kit comprising a combination therapeutic product composed of sodium phenylbutyrate or glycerol phenylbutyrate and sodium benzoateIn December 2022, Acer announced FDA approval of OLPRUVA™ (sodium phenylbutyrate) for oral suspension, a prescription medicine used along with certain therapy, including changes in diet, for the long-term management of adults and children weighing 44 pounds (20 kg) or greater and with a body surface area (BSA) of 1.2 m2 or greater, with UCDs, involving deficiencies of CPS, OTC or AS. OLPRUVA™ is not used to treat rapid increase of ammonia in the blood (acute hyperammonemia), which can be life-threatening and requires emergency medical treatment. More information is available at www.OLPRUVA.comIn March 2023, Acer announced an update on its OLPRUVA™ U.S. commercial launch activities, including the ongoing addition of commercial and medical affairs resources, the introduction of its OLPRUVA™ Navigator by Acer Therapeutics patient support service, a predictable and responsible price commitment, and anticipated drug availability by early July 2023 (subject to additional capital)In March 2023, Acer announced results from a survey designed to quantify preferences of healthcare providers for Urea Cycle Disorders (UCDs) presented at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting. The authors concluded that optimizing nitrogen-binding medications for UCD treatment to facilitate and encourage increased patient adherence through masking taste/odor and/or enhancing other aspects of the patient experience may support improved outcomes in UCDs EDSIVO™ (celiprolol) In October 2022, Acer announced that the USPTO issued a Notice of Allowance for Acer’s patent application No. 16/930,208 and subsequently issued on December 13, 2022, as US Patent #11,523,997, for claims related to certain methods of treating vascular Ehlers-Danlos syndrome (vEDS) with celiprolol ACER-801 (osanetant) In March 2023, Acer announced that topline results from Acer’s Phase 2a proof of concept clinical trial to evaluate ACER-801 (osanetant) as a potential treatment for moderate to severe Vasomotor Symptoms (VMS) associated with menopause showed that ACER-801 was safe and well-tolerated but did not achieve statistical significance when evaluating ACER-801’s ability, when compared to placebo, to decrease the frequency or severity of hot flashes in postmenopausal women. As a result, Acer is pausing the ACER-801 program until Acer has conducted a thorough review of the full data set Corporate Ended Q4 2022 with $2.3 million in cash and cash equivalents. Acer believes its cash and cash equivalents available at December 31, 2022, together with the gross proceeds of $7.0 million from a second term loan with SWK Funding LLC which closed on January 31, 2023, $4.1 million from Acer’s ATM facility subsequent to December 31, 2022, and $2.7 million from a sale of securities (including pursuant to a registered direct offering of shares of common stock and prefunded warrants) which closed on March 24, 2023, will be sufficient to fund Acer’s anticipated operating and capital requirements into the middle of Q2 2023 Anticipated Milestones (Subject to Available Capital) Q2 2023: Acer intends to continue to add resources to establish its commercial and medical affairs presence in the U.S. in support of its OLPRUVA™ launch expected in Q2 2023 Q2 2023: Negotiations with the major commercial payers and state Medicaid organizations regarding access for OLPRUVA™ are ongoing, and representatives from Acer’s OLPRUVA™ Navigator by Acer Therapeutics patient support service are expected to begin accepting prescriptions in late Q2 2023Q2 2023: Acer expects OLPRUVA™ wholesale acquisition cost (WAC) pricing to be listed publicly in Q2 2023Early July 2023: Acer anticipates OLPRUVA™ drug availability in early July 2023Q4 2023: Acer anticipates completing enrollment in its ongoing, pivotal Phase 3 DiSCOVER trial of EDSIVO™ (celiprolol) in patients with COL3A1-positive vEDS. The double-blind portion of the DiSCOVER trial is designed to end if statistical significance is reached at an interim analysis which occurs at accrual of 28 vEDS-related events, estimated to occur as early as approximately 18 months after completion of full enrollment, or after accrual of 46 vEDS-related clinical eventsAcer intends to explore additional lifecycle opportunities for OLPRUVA™ (sodium phenylbutyrate) in various disorders where proof of concept data exists, including in Maple Syrup Urine Disease (MSUD), Pyruvate Dehydrogenase Complex Deficiency (PCDC), rare pediatric epilepsies and various liver disorders Q4 and Full Year 2022 Financial Results Cash Position. Cash and cash equivalents were $2.3 million as of December 31, 2022, compared to $12.7 million as of December 31, 2021. Acer believes its cash and cash equivalents as of December 31, 2022, together with the gross proceeds of $7.0 million from a second term loan with SWK Funding LLC which closed on January 31, 2023, $4.1 million from Acer’s ATM facility subsequent to December 31, 2022, and $2.7 million from a sale of securities (including pursuant to a registered direct offering of shares of common stock and prefunded warrants) which closed on March 24, 2023, will be sufficient to fund its currently anticipated operating and capital requirements into the middle of Q2 2023. Research and Development Expenses. Research and development expenses were $2.6 million, net of collaboration funding of $1.0 million, for the three months ended December 31, 2022, as compared to $1.7 million, net of collaboration funding of $1.3 million, for the three months ended December 31, 2021. Research and development expenses for the three months ended December 31, 2022 were comprised of $1.1 million related to ACER-001, offset by $1.0 million of collaboration funding; $1.2 million related to ACER-801; $1.0 million related to EDSIVO™; and $0.3 million related to other development activities. Research and development expenses were $11.9 million, net of collaboration funding of $7.8 million, for the year ended December 31, 2022, as compared to $6.5 million, net of collaboration funding of $6.1 million, for the year ended December 31, 2021. This increase of $5.4 million was primarily due to increases in employee-related expenses and expenses related to clinical studies, partially offset by the increase in recognition of contra-expense from the collaboration funding from Acer’s Collaboration and License Agreement with Relief Therapeutics Holding AG (Relief) for the development and commercialization of OLPRUVA™ (Collaboration Agreement). General and Administrative Expenses. General and administrative expenses were $2.6 million, net of collaboration funding of $1.2 million, for the three months ended December 31, 2022, as compared to $3.1 million, net of collaboration funding of $1.6 million, for the three months ended December 31, 2021. General and administrative expenses were $12.7 million, net of collaboration funding of $8.2 million, for the year ended December 31, 2022, as compared to $10.7 million, net of collaboration funding of $3.2 million, for the year ended December 31, 2021. This increase of $2.0 million was primarily due to increases in precommercial activities, employee-related expenses, professional services, as well as information technology, partially offset by the increase in the recognition of contra-expense from the collaboration funding from the Collaboration Agreement with Relief. Net Loss. Net loss for the three months ended December 31, 2022 was $9.4 million, or $0.54 net loss per share (basic and diluted), compared to a net loss of $4.4 million, or $0.31 net loss per share (basic and diluted), for the three months ended December 31, 2021. Net loss for the year ended December 31, 2022 was $26.2 million, or $1.66 net loss per share (basic and diluted), compared to a net loss of $15.4 million, or $1.08 net loss per share (basic and diluted), for the year ended December 31, 2021. For additional information, please see Acer’s Annual Report on Form 10-K filed today with the SEC. About Acer TherapeuticsAcer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. In the U.S., OLPRUVA™ (sodium phenylbutyrate) is approved for the treatment of urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). Acer is also advancing a pipeline of investigational product candidates for rare and life-threatening diseases, including: OLPRUVA™ (sodium phenylbutyrate) for treatment of various disorders, including Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-801 (osanetant) for treatment of Vasomotor Symptoms (VMS), post-traumatic stress disorder (PTSD) and prostate cancer. For more information, visit www.acertx.com. Acer Forward-Looking StatementsThis press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. Examples of such statements include, but are not limited to, statements about plans for the commercialization of OLPRUVA™ for oral suspension in the U.S. for the treatment of certain patients with UCDs involving deficiencies of CPS, OTC, or AS, including negotiations with commercial payers and Medicaid organizations regarding access as well as the timing of drug availability and the expected commercial launch, statements about plans and potential milestones for the continued clinical development of OLPRUVA™ in other indications, statements about plans and potential milestones for the continued clinical development of EDSIVO™ for treatment of vEDS in patients with a confirmed type III collagen (COL3A1) mutation, statements about plans for the development of ACER-801, statements about our anticipated 2023 milestones, and statements about our capital requirements and sufficiency and duration of our current cash and cash equivalents. Our efforts to commercialize OLPRUVA™ for oral suspension in the U.S. for the treatment of certain patients with UCDs involving deficiencies of CPS, OTC, or AS are at an early stage, we currently do not have fully developed marketing, sales or distribution capabilities, and there is no guarantee that we will be successful in our commercialization efforts. Our pipeline products (including OLPRUVA™ for indications other than UCDs as well as EDSIVO™ and ACER-801) are under investigation and their safety and efficacy have not been established and there is no guarantee that any of our investigational products in development will receive health authority approval or become commercially available for the uses being investigated. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the availability of financing to fund our commercialization efforts, our pipeline product development programs and our general corporate operations as well as risks related to drug development and the regulatory approval process, including the timing and requirements of regulatory actions. We disclaim any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. You should review additional disclosures we make in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. You may access these documents for no charge at http://www.sec.gov. ACER THERAPEUTICS INC.CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended Years Ended December 31, December 31, 2022 2021 2022 2021 (unaudited) Revenue$— $360,000 $— $1,260,000 Operating expenses: Research and development (in the three months ended December 31, 2022 and 2021, net of collaboration funding of $999,183 and $1,288,376, respectively, and in the twelve months ended December 31, 2022 and 2021, net of collaboration funding of $7,825,263 and $6,055,295, respectively)$2,644,745 $1,705,402 $11,924,837 $6,508,055 General and administrative development (in the three months ended December 31, 2022 and 2021, net of collaboration funding of $1,186,048 and $1,636,535, respectively, and in the twelve months ended December 31, 2022 and 2021, net of collaboration funding of $8,248,813 and $3,197,659, respectively) 2,618,378 3,074,325 12,689,422 10,700,334 Total operating expenses 5,263,123 4,779,727 24,614,259 17,208,389 Loss from operations (5,263,123) (4,419,727) (24,614,259) (15,948,389) Other (expense) income, net: Costs of debt issuance (229,500) — (1,720,094) — Changes in fair value of debt instruments (loss) gain (3,846,472) — 245,138 — Interest and other income (expense), net 21,209 (2,641) (101,432) 519,639 Foreign currency transaction (loss) gain (66,444) 1,725 (46,668) 54,757 Total other (expense) income, net (4,121,207) (916) (1,623,056) 574,396 Net loss$(9,384,330) $(4,420,643) $(26,237,315) $(15,373,993) Net loss per share - basic$(0.54) $(0.31) $(1.66) $(1.08) Weighted average common shares outstanding - basic 17,359,964 14,310,244 15,767,152 14,268,245 Net loss per share - diluted$(0.54) $(0.31) $(1.66) $(1.08) Weighted average common shares outstanding - diluted 17,359,964 14,310,244 15,767,152 14,268,245 SELECTED BALANCE SHEET DATA: December 31, December 31, 2022 2021 Cash and cash equivalents $2,329,218 $12,710,762 Collaboration receivable $— $5,000,000 Prepaid expenses $759,292 $1,094,229 Deferred financing costs $408,000 $— Other current assets $20,188 $9,283,625 Property and equipment, net $214,578 $114,112 Total assets $11,624,226 $36,256,951 Deferred collaboration funding $8,412,971 $24,487,047 Original Term Loan payable, at fair value $5,567,231 $— Convertible note payable, at fair value $6,047,532 $— Total liabilities $28,385,498 $37,980,556 Total stockholders’ deficit $(16,761,272) $(1,723,605) Corporate and IR Contact Jim DeNikeAcer Therapeutics Inc.jdenike@acertx.com+1-844-902-6100 Nick ColangeloGilmartin Groupnick@gilmartinIR.com+1-332-895-3226